Immunic, Inc. (IMUX)
| Market Cap | 227.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -76.54M |
| Shares Out | 26.25M |
| EPS (ttm) | -3.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 192,524 |
| Open | 8.49 |
| Previous Close | 8.39 |
| Day's Range | 8.30 - 8.70 |
| 52-Week Range | 6.96 - 28.21 |
| Beta | 1.94 |
| Analysts | Buy |
| Price Target | 54.50 (+528.6%) |
| Est. Earnings Date | Nov 4, 2021 |
About IMUX
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intes...
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for Immunic stock is "Buy." The 12-month stock price forecast is 54.50, which is an increase of 528.60% from the latest price.
News
Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer
NEW YORK, Oct. 14, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic ...
Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple Sclerosis
NEW YORK, Sept. 30, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic...
Immunic, Inc. to Participate in Scientific and Investor Conferences in October
NEW YORK, Sept. 28, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic...
Immunic, University Medical Center Goettingen Ink Licensing Pact For Combination Viral Infection Treatments
Immunic Inc (NASDAQ: IMUX) has executed an in-license agreement with the University Medical Center Goettingen covering the combination of DHODH inhibitors and nucleoside analogs to treat viral infection...
Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibit...
NEW YORK and GOETTINGEN, Germany, Sept. 22, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies foc...
Immunic, Inc. to Participate in Investor and Scientific Conferences in September
NEW YORK, Sept. 8, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic ...
Immunic, Inc. Reports Second Quarter 2021 Financial Results and Highlights Recent Activity
NEW YORK, Aug. 6, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic i...
Immunic, Inc. to Participate in Investor Conferences in August
NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic i...
Immunic, Inc. Announces Closing of $45.0 Million Public Offering
NEW YORK, July 19, 2021 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on t...
Why Immunic Plummeted by 21% on Thursday
Word of a new share issue made investors feel queasy.
Immunic Stock Is Trading Lower After Equity Raise Of $45M To Fund Lead Pipeline Candidates
Immunic Inc (NASDAQ: IMUX) has priced an underwritten public offering of 4.5 million shares at $10 per share, representing a discount of about 16% from the last close price of $11.89 on Wednesday. The g...
Immunic, Inc. Announces Pricing of $45 Million Public Offering of Common Stock
NEW YORK, July 15, 2021 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on t...
Immunic, Inc. Announces Proposed Public Offering of Common Stock
NEW YORK, July 14, 2021 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on t...
Immunic, Inc. to Host Virtual R&D Day Today to Provide an Update on the Preclinical and Clinical Development of IMU-9...
NEW YORK, July 12, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic ...
Immunic Stock Jumps As FDA Signs Off On 2 Clinical Trial Applications
The FDA has signed off Immunic Inc's (NASDAQ: IMUX) investigational new drug application for the Phase 3 ENSURE program of lead asset IMU-838 in patients with relapsing-remitting multiple sclerosis. In...
Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Scleros...
NEW YORK, July 1, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammat...
Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in July
NEW YORK, June 28, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...
Immunic, Inc. to Participate in Industry and Investor Conferences in June
NEW YORK, June 10, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...
Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel
NEW YORK, June 1, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inf...
Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent Activity
NEW YORK, May 6, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammato...
Why PPD, Immunic, Inovio and CureVac Shares Are Higher Today
PPD, Inc. (NASDAQ: PPD), Immunic, Inc. (NASDAQ: IMUX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and CureVac N.V. (NASDAQ: CVAC) are among the healthcare movers on Thursday.
Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remit...
NEW YORK, April 15, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflamm...
Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April
NEW YORK, April 13, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic i...
Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic's Lead Program, IMU-838
NEW YORK and PLANEGG-MARTINSRIED, Germany, March 31, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology ther...
Immunic Gets Bullish Rating On Multiple Sclerosis Drug Prospect
Immunic Inc's (NASDAQ: IMUX) lead candidate, IMU-838, has an “attractive safety profile” and exhibited positive efficacy results in the Phase II trials, according to JMP Securities. The Immunic Analyst:...